ACC-NK (Antibody-cell Conjugate NK) integrates the antigen-targeting function of antibodies and the immune killing function of NK cells through antibody conjugation technology (non-viral vector, non-gene editing). By targeting specific tumor antigens with antibodies, it can quickly and efficiently guide NK cells to recognize and kill tumor cells.
Preventing tumor recurrence after surgery
Solid tumor treatment
Warburg combined with NK treatment for advanced solid tumors
Proton and heavy ion therapy combined with NK cell therapy for solid tumors
胚胎滋养层糖蛋白(5T4)是一种N糖基化跨膜蛋白，参与胚胎细胞免疫豁免过程，5T4高表达于胚胎滋养层细胞，覆盖90%以上实体瘤。5T4在癌前病变(如结肠息肉、肺结节)中已表达，ACC-NK854可早期清除，阻断癌变进程。
英百瑞针对Trop-2的ACC-NK细胞疗法为全球首创疗法，具有IO+ADC巨大的治疗潜力；规避了针对Trop-2的ADC产品毒性强，治疗窗口较小等问题和隐患，ACC-NK822提供了一种新的治疗范式，与ADC、放化疗联用可以减少副作用，显著增强疗效，延长病人生存期。
CD33-CLL1双靶点FIC疗法同时针对AML细胞和白血病干细胞进行杀伤。对于抑制改善血液肿瘤晚期具有非常显著的疗效。
Scan the QR code to learn more
Consultation Hotline400-995-9976
Copyright2025 英百瑞（杭州）医学研究有限公司 All Rights Reserved. 浙ICP备2025205905号 DESIGN BY : WEETOP
